-
Leerink Partners Downgrades Innate Pharma S.A. (IPHA) to Market Perform
-
BTIG Starts Innate Pharma S.A. (IPHA) at Buy
-
Innate Pharma (IPHA) Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502
-
H.C. Wainwright Reiterates Buy Rating on Innate Pharma S.A. (IPHA)
-
H.C. Wainwright Reiterates Buy Rating on Innate Pharma S.A. (IPHA)
-
H.C. Wainwright Reiterates Buy Rating on Innate Pharma S.A. (IPHA)
-
Innate Pharma (IPHA) Appoints Jonathan Dickinson as CEO and Board Chair
-
H.C. Wainwright Reiterates Buy Rating on Innate Pharma S.A. (IPHA)

